Remote Collection of Patient Reported Toxicity Using SMS Text Messaging (CareSignal)

The Washington University

Status: Completed

Conditions: Cancer

Treatments: Other: CareSignal

Study type: Observational

Funder types: Other

Identifiers

NCT04437472

202005063

Details and patient eligibility

About

CareSignal has developed an application that allows for remote collection of patient-reported data such as symptoms or outcomes on any device compatible with the short message service (SMS), otherwise known as "text messaging". The software can be configured to complete symptom monitoring by surveying patients about toxicity using the PRO-CTCAE tools. PRO-CTCAE is the patient reported outcomes version of the CTCAE that was designed by the National Cancer Institute (NCI) for use in clinical trials.

Enrollment: 30 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Currently planning to receive radiotherapy for 2 or more fractions with or without chemotherapy.
• Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
• Age 18 years or older.

Exclusion criteria

-Unable to reliably access and use a device compatible with CareSignal software.

Trial design

30 participants in 1 patient group

CareSignal

Description:

-Participants will undergo a single training session on how to use the CareSignal software no more than 4 weeks before starting standard of care therapy. After the training session, patients will be encouraged by the treatment team to complete the baseline symptom report once they receive the questions via SMS prior to starting any therapy and to complete the weekly reports during therapy and in follow up.

Treatment:

Other: CareSignal